Lucid Diagnostics Inc.
NASDAQ:LUCDMedical - Devices
+$0.04 today
- Market cap
- $79.38M
- Beta
- 1.08
- P/E (TTM)
- -2.3
- EPS (TTM)
- -$0.44
Volume 2.70M
Average 0.84M
LUCD Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Lucid Diagnostics Inc.NASDAQ: LUCD
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $1.21M fell 15.5% year over year, behind the -7.8% change in trailing-twelve-month research & development. Sequentially, it fell 30.0% from the prior quarter. Over 3 fiscal years it compounded at +691.2% a year.
Context
- Research & development amounted to 120654.5% of revenue in FY2025, up 120516.6 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -15.5% toward the trailing-twelve-month pace of -7.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 5.68B USD
- Year-over-year change
- +94659.7%
- 4-year CAGR
- +397.1%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.68B | +94659.7% |
| FY2024 | 2024-12-31 | 5.99M | -17.4% |
| FY2023 | 2023-12-31 | 7.25M | -36.8% |
| FY2022 | 2022-12-31 | 11.47M | +23.3% |
| FY2021 | 2021-12-31 | 9.3M | — |
Research & Development vs competitors
How LUCD compares with its peers on the latest reported figures
- LUCD's LTM Mar 2026 research & development of $5.46M is the 8th highest of the 10 companies compared; the peer median is $20.18M.
- Its year-over-year change of -7.8% is the 7th highest of 10, against a peer median of -5.9%.
- Research & development amounts to 106.3% of revenue for LUCD, versus a peer median of 63.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
AVRAnteris Technologies Global Corp. | LTM Mar 2026 | $70.12M | +24.4% | +57.8% | 3788.3% |
| LTM Mar 2026 | $41.33M | -11.2% | -6.2% | 274.8% | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $33.44M | +11.2% | +29.0% | 279.0% |
| LTM Mar 2026 | $21.46M | +138.8% | +31.8% | 63.4% | |
| LTM Mar 2026 | $20.18M | -5.9% | +14.6% | 27.9% | |
| LTM Mar 2026 | $15.13M | +46.7% | -20.4% | 14.1% | |
| LTM Mar 2026 | $13.34M | -7.2% | +1.9% | 38.8% | |
| LTM Mar 2026 | $5.46M | -7.8% | +691.2% | 106.3% | |
| LTM Mar 2026 | $3.33M | -25.7% | -9.5% | 6.0% | |
| LTM Mar 2026 | $319.38K | -20.4% | -50.4% | 80.5% | |
| Peer median (excluding LUCD) | $20.18M | -5.9% | +1.9% | 63.4% | |
Competitors are the stored peer set for LUCD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 500K | 377K | 2.43M | 4.35M | 4.71M |
| Cost of Revenue | 585K | 3.61M | 8.48M | 8.27M | 7.54M |
| Gross Profit | (85K) | (3.24M) | (6.05M) | (3.92M) | (2.84M) |
| Gross Margin | -17.0% | -858.6% | -249.2% | -90.2% | -60.3% |
| Research & Development | 9.3M | 11.47M | 7.25M | 5.99M | 5.68B |
| Selling, General & Admin | 18.04M | 39.82M | 35.66M | 36.62B | 41.58B |
| Operating Expenses | 27.33M | 52.93M | 42.43M | 42.13M | 46.8M |
| Depreciation & Amortization | 4K | 1.94M | 2.5M | 1.17M | 872K |
| EBITDA | (27.42M) | (54.23M) | (49.75M) | (44.34M) | (57.12M) |
| EBITDA Margin | -5483.0% | -14383.8% | -2049.1% | -1020.2% | -1213.7% |
| Operating Income | (27.42M) | (56.17M) | (48.48M) | (46.05M) | (49.64M) |
| Operating Margin | -5483.8% | -14899.5% | -1996.8% | -1059.6% | -1054.8% |
| Interest Income | 0 | 88K | 424K | 322K | 386K |
| Interest Expense | 659K | 8K | 416K | 26K | 22K |
| Other Income / Expenses | (659K) | 0 | (4.18M) | 523K | (8.37M) |
| Income Before Tax | (28.08M) | (56.17M) | (52.67M) | (45.53M) | (58.01M) |
| Pre-Tax Margin | -5615.6% | -14899.5% | -2169.1% | -1047.6% | -1232.7% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (28.08M) | (56.17M) | (52.67M) | (45.53M) | (58.01M) |
| Net Margin | -5615.6% | -14899.5% | -2169.1% | -1047.6% | -1232.7% |
| EPS (Basic) | (0.78) | (1.55) | (1.26) | (1.05) | (0.69) |
| EPS (Diluted) | (0.78) | (1.55) | (1.26) | (1.05) | (0.69) |
| Weighted Avg Shares | 36.06M | 36.17M | 41.76M | 50.52M | 101.95M |
| Weighted Avg Shares (Diluted) | 36.06M | 36.17M | 41.76M | 50.52M | 101.95M |
Lucid Diagnostics Inc.
NASDAQ:LUCD
Intrinsic Alpha fair value
Locked
Current Price
$0.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.